Class I Phosphatidylinositol 3-Kinases
"Class I Phosphatidylinositol 3-Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A phosphatidylinositol 3-kinase subclass that includes enzymes with a specificity for 1-phosphatidylinositol, 1-phosphatidylinositol 4-phosphate, and 1-phosphatidylinositol 4,5-bisphosphate. Members of this enzyme subclass are activated by cell surface receptors and occur as heterodimers of enzymatic and regulatory subunits.
| Descriptor ID |
D058534
|
| MeSH Number(s) |
D08.811.913.696.620.500.100.100 D08.811.913.696.620.500.200.100 D12.776.476.162
|
| Concept/Terms |
Class I Phosphatidylinositol 3-Kinases- Class I Phosphatidylinositol 3-Kinases
- Class I Phosphatidylinositol 3 Kinases
- Class I Phosphatidylinositol 3-Kinase
- Class I Phosphatidylinositol 3 Kinase
- Phosphatidylinositol 3-Kinase, Class I
- Phosphatidylinositol 3 Kinase, Class I
|
Below are MeSH descriptors whose meaning is more general than "Class I Phosphatidylinositol 3-Kinases".
Below are MeSH descriptors whose meaning is more specific than "Class I Phosphatidylinositol 3-Kinases".
This graph shows the total number of publications written about "Class I Phosphatidylinositol 3-Kinases" by people in this website by year, and whether "Class I Phosphatidylinositol 3-Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 4 | 4 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 5 | 5 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 2 | 3 | 5 |
| 2018 | 1 | 2 | 3 |
| 2019 | 4 | 2 | 6 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 2 | 2 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Class I Phosphatidylinositol 3-Kinases" by people in Profiles.
-
Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome. Orphanet J Rare Dis. 2025 Jul 25; 20(1):375.
-
Molecular and clinical determinants of response to checkpoint inhibitor immunotherapy in glioblastoma. J Neurooncol. 2025 Oct; 175(1):453-461.
-
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024 11 25; 15(1):10213.
-
Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies. Blood Adv. 2024 10 22; 8(20):5279-5289.
-
Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study. Target Oncol. 2024 Nov; 19(6):981-990.
-
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2024 Oct; 189:138-145.
-
Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes. JCO Precis Oncol. 2024 03; 8:e2300124.
-
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Ka Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia. Cancer Discov. 2024 Feb 08; 14(2):240-257.
-
Systematic review of mortality and survival rates for APDS. Clin Exp Med. 2024 Jan 27; 24(1):17.
-
HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study. Urol Oncol. 2023 12; 41(12):486.e15-486.e23.